New Horizons in Treating Metastatic Disease

Flamm-Honing, 1996, Treatment of metastatic disease, 669 Kardinal, 1996, Chemotherapy of breast cancer, 1125 Nabholtz, 1999, The role of taxanes in the management of breast cancer, Semin Oncol, 26, 1 Wani, 1971, Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia, J Am Chem Soc, 93, 2325, 10.1021/ja00738a045 Kumar, 1981, Taxol-induced polymerization of purified tubulin. Mechanism of action, J Biol Chem, 256, 10435, 10.1016/S0021-9258(19)68639-4 Liebmann, 1993, Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines, Br J Cancer, 68, 1104, 10.1038/bjc.1993.488 Raymond, 1997, Effects of prolonged versus short-term exposure paclitaxel (Taxol) on human tumor colony-forming units, Anticancer Drugs, 8, 379, 10.1097/00001813-199704000-00011 Seidman, 1995, Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response, J Clin Oncol, 13, 1152, 10.1200/JCO.1995.13.5.1152 Holmes, 1991, Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer, J Natl Cancer Inst, 83, 1797, 10.1093/jnci/83.24.1797-a Seidman, 1995, Phase II trial of paclitaxel by 3- hour infusion as initial and salvage chemotherapy for metastatic breast cancer, J Clin Oncol, 13, 2575, 10.1200/JCO.1995.13.10.2575 Smith, 1999, Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26, J Clin Oncol, 17, 3403, 10.1200/JCO.1999.17.11.3403 Wilson, 1994, Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion, J Clin Oncol, 12, 1621, 10.1200/JCO.1994.12.8.1621 Seidman, 1996, Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer, J Clin Oncol, 14, 1877, 10.1200/JCO.1996.14.6.1877 Holmes, 1998, Final results: randomized phase III trial of paclitaxel by 3-hr versus 96-hr infusion in patients (pt) with met breast cancer (MBC). The long & short of it, Proc Am Soc Clin Oncol, 17, 110a Zujewski, 1998, A phase I trial of paclitaxel by 14-day continuous intravenous infusion in metastatic cancer, Cancer Therapeutics, 1, 302 Seidman, 1997, Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancer, Semin Oncol, 24, S17 Sikov, 1998, Weekly high-dose paclitaxel (P) demonstrates significant activity in advanced breast cancer (BC), Proc Am Soc Clin Oncol, 17, 112a Seidman, 1998, One-hour paclitaxel via weekly infusion: dose-density with enhanced therapeutic index, Oncology (Huntingt), 12, 19 Perez, 1999, A large phase II trial of paclitaxel administered as a weekly one hour infusion in patients with metastatic breast cancer, Proc Am Soc Clin Oncol, 18, 126a Klauber, 1997, Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol, Cancer Res, 57, 81 Hrushesky, 1985, Circadian timing of cancer chemotherapy, Science, 228, 73, 10.1126/science.3883493 Ezzat, 1997, A phase II trial of circadian-timed paclitaxel and cisplatin therapy in metastatic breast cancer, Ann Oncol, 8, 663, 10.1023/A:1008228121390 Extra, 1993, Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion, Cancer Res, 53, 1037 Burris, 1993, Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion, J Clin Oncol, 11, 950, 10.1200/JCO.1993.11.5.950 Bissett, 1993, Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion, Cancer Res, 53, 523 van Oosterom, 1995, Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: clinical experience, Anticancer Drugs, 6, 356, 10.1097/00001813-199506000-00002 Trudeau, 1996, Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group, J Clin Oncol, 14, 422, 10.1200/JCO.1996.14.2.422 Hortobagyi, 1997, Docetaxel in breast cancer and a rationale for combination therapy, Oncology (Huntingt), 11, 11 Fumoleau, 1996, A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC, Ann Oncol, 7, 165, 10.1093/oxfordjournals.annonc.a010544 Valero, 1995, Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer, J Clin Oncol, 13, 2886, 10.1200/JCO.1995.13.12.2886 Bonneterre, 1999, Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience, Eur J Cancer, 35, 1431, 10.1016/S0959-8049(99)00174-4 Nabholtz, 1998, Taxotere (T) improves survival over mitomycin C vinblastine (MV) in patients (pts) with metastatic breast cancer (MBC) who have failed an anthracycline (ant) containing regimen: final results of a phase III randomized trial, Proc Am Soc Clin Oncol, 17, 101a Hakamies-Blomqvist, 2000, Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group, Eur J Cancer, 36, 1411, 10.1016/S0959-8049(00)00126-X Monnier A, Bonneterre J, Roche H, et al. Phase III study: Taxotere (TXT) versus 5-fluorouracil + navelbine (FUN) in patients (pts) with metastatic breast cancer (MBC) as 2nd line chemotherapy (CT). preliminary results. Presented at: 23rd European Society for Medical Oncology Congress, Athens, Greece, November 6-10, 1998 (Abstract #580). Chan, 1999, Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group, J Clin Oncol, 17, 2341, 10.1200/JCO.1999.17.8.2341 Dieras, 1997, Docetaxel in combination with doxorubicin: a phase I dose-finding study, Oncology (Huntingt), 11, 17 Dieras, 1998, Phase II study of taxotere (T) in combination with doxorubicin (A) as 1st line chemotherapy (CT) of metastatic breast cancer (MBC), Br Cancer Res Treat, 50, 262 Nabholtz, 1999, A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC, Proc Am Soc Clin Oncol, 18, 127a Hainsworth, 1998, Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer, J Clin Oncol, 16, 2164, 10.1200/JCO.1998.16.6.2164 Löffler, 1998, Activity of weekly Taxotere® (TXT) in patients with metastatic breast cancer, Proc Am Soc Clin Oncol, 17, 113a Burstein, 2000, Docetaxel administered on a weekly basis for metastatic breast cancer, J Clin Oncol, 18, 1212, 10.1200/JCO.2000.18.6.1212 Schimming, 1999, [Inhibition of tumor neoangiogenesis and induction of apoptosis as properties of docetaxel (taxotere)], Mund Kiefer Gesichtschir, 3, 210, 10.1007/s100060050132 Gianni, 1995, Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dosefinding and sequence-finding study, J Clin Oncol, 13, 2688, 10.1200/JCO.1995.13.11.2688 Gehl, 1996, Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic, Ann Oncol, 7, 687, 10.1093/oxfordjournals.annonc.a010717 Ormrod, 1999, Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer, Drugs Aging, 15, 389, 10.2165/00002512-199915050-00006 Cersosimo, 1986, Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue, J Clin Oncol, 4, 425, 10.1200/JCO.1986.4.3.425 Habeshaw, 1991, Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial, J Clin Oncol, 9, 295, 10.1200/JCO.1991.9.2.295 Focan, 1993, Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial, J Clin Oncol, 11, 1253, 10.1200/JCO.1993.11.7.1253 French Epirubicin Study Group, 1988, A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin, J Clin Oncol, 6, 679, 10.1200/JCO.1988.6.4.679 Italian Multicentre Breast Study with Epirubicin, 1988, Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial, J Clin Oncol, 6, 976, 10.1200/JCO.1988.6.6.976 Heidemann, 1990, Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer, Onkologie, 13, 24, 10.1159/000216714 Luck, 1998, Metastatic breast cancer: experience with the combination paclitaxel plus epirubicin, Oncology (Huntingt), 12, 36 Conte, 1998, Paclitaxel plus epirubicin in advanced breast cancer, Oncology (Huntingt), 12, 40 Carmichael, 1997, A phase II trial of epirubicin plus paclitaxel in metastatic breast cancer. United Kingdom Coordinating Committee for Cancer Research Breast Cancer Sub-Committee, Semin Oncol, 24, S17 Ries, 1997, Phase I/II clinical trial of epirubicin and paclitaxel followed by granulocyte colony-stimulating factor in a 2- week schedule in patients with advanced or metastatic breast cancer, Semin Oncol, 24, S17 Kohler, 1997, Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer: results of a clinical phase II study, Semin Oncol, 24, S17 Pagani, 1999, Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer, Ann Oncol, 10, 539, 10.1023/A:1026437731354 Trudeau, 1999, Escalating doses of docetaxel and epirubicin as first line therapy for metastatic breast cancer. a phase I/II study of the National Cancer Institute of Canada-Clinical Trials Group, Proc Am Soc Clin Oncol, 18, 117a Kerbrat, 1998, Docetaxel (D) in combination with epirubicin (E) as 1st line chemotherapy (CT) of metastatic breast cancer (MBC): final results, Proc Am Soc Clin Oncol, 17, 151a Luck, 2000, Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC). epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC). A study of the Ago Breast Cancer Group, Proc Am Soc Clin Oncol, 19, 73a Pasqualini, 2000, Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis, Cancer Res, 60, 722 Keane, 1999, Chemotherapy augments TRAIL-induced apoptosis in breast cell lines, Cancer Res, 59, 734 Diasio, 1989, Clinical pharmacology of 5-fluorouracil, Clin Pharmacokinet, 16, 215, 10.2165/00003088-198916040-00002 Ansfield, 1969, A ten-year study of 5- flurouracil in disseminated breast cancer with clinical results and survival times, Cancer Res, 29, 1062 Petrelli, 1987, A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5- fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma, J Clin Oncol, 5, 1559, 10.1200/JCO.1987.5.10.1559 Lokich, 1989, A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study, J Clin Oncol, 7, 425, 10.1200/JCO.1989.7.4.425 Saltz, 1995, A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer, Cancer, 75, 782, 10.1002/1097-0142(19950201)75:3<782::AID-CNCR2820750306>3.0.CO;2-I Baker, 1996, Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase, J Clin Oncol, 14, 3085, 10.1200/JCO.1996.14.12.3085 Budman, 1998, Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine, J Clin Oncol, 16, 1795, 10.1200/JCO.1998.16.5.1795 Blum, 1999, Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer, J Clin Oncol, 17, 485, 10.1200/JCO.1999.17.2.485 O'Shaughnessy, 1998, A randomized phase II study of Xeloda™ (capecitabine) vs CMF as first line chemotherapy of breast cancer in women aged > 55 years, Proc Am Soc Clin Oncol, 17, 103a Moiseenko, 2000, [A comparative randomized phase-II study of Xeloda (capecitabine) and paclitaxel in patients with breast cancer progressing after anthracycline antibiotics], Vopr Onkol, 46, 285 Khoury, 1998, Phase I study of capecitabine in combination with paclitaxel in patients with previously treated metastatic breast cancer, Proc Am Soc Clin Oncol, 17, 206a Sole, 1995, Phase II trial of an all-oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancer, Cancer, 75, 831, 10.1002/1097-0142(19950201)75:3<831::AID-CNCR2820750314>3.0.CO;2-S Daniels, 1993, Phase II trial of UFT activity in pretreated breast cancer patients, Jpn J Clin Oncol, 23, 363 Kajanti, 1993, Oral tegafur in the treatment of metastatic breast cancer: a phase II study, Eur J Cancer, 6, 863, 10.1016/S0959-8049(05)80426-5 Pazdur, 1994, Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma, J Clin Oncol, 12, 2296, 10.1200/JCO.1994.12.11.2296 Richardet, 1999, Uracil/tegafur plus oral calcium folinate in advanced breast cancer, Oncology (Huntingt), 13, 96 Klaassen, 1999, Oral UFT/leucovorin (LV) in combination with paclitaxel (P) in the second line treatment of patients (pts) with metastatic breast cancer (MBC): results of a phase I/II trial, Proc Am Soc Clin Oncol, 18, 107a Burris, 1999, Eniluracil/5FU in anthracycline and taxane refractory breast cancer, Proc Am Soc Clin Oncol, 18, 107a Smith, 2000, Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: a phase II study, J Clin Oncol, 18, 2378, 10.1200/JCO.2000.18.12.2378 Gottlieb, 1970, Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880), Cancer Chemother Rep, 54, 461 Jain, 1998, Induction of DNA damage, inhibition of DNA synthesis, and suppression of c-myc expression by the topoisomerase I inhibitor, camptothecin, in MCF-7 human breast tumor cells, Biochem Pharmacol, 55, 1263, 10.1016/S0006-2952(97)00618-7 Wadkins, 1999, Water soluble 20(S)-glycinate esters of 10,11-methylenedioxycamptothecins are highly active against human breast cancer xenografts, Cancer Res, 59, 3424 Kumazawa, 1998, Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice, Cancer Chemother Pharmacol, 42, 210, 10.1007/s002800050807 Abigerges, 1995, Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients, J Clin Oncol, 13, 210, 10.1200/JCO.1995.13.1.210 Rowinsky, 1994, Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1- piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks, Cancer Res, 54, 427 Taguchi, 1990, [Phase I clinical study of CPT- 11. Research group of CPT-11], Gan To Kagaku Ryoho, 17, 115 Taguchi, 1994, [An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with advanced breast cancer], Gan To Kagaku Ryoho, 21, 83 Taguchi, 1994, [A late phase II study of CPT-11 (irinotecan) in advanced breast cancer. CPT-11 Study Group on Breast Cancer], Gan To Kagaku Ryoho, 21, 1017 Bonneterre, 1993, A phase II study of a new camptothecin analogue CPT-11 in previously treated advanced breast cancer patients, Proc Am Soc Clin Oncol, 12, 94a Chang, 1997, The potential role of topotecan in the treatment of advanced breast cancer, Semin Oncol, 24, S20 Gerrits, 1998, Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours, Eur J Cancer, 34, 1030, 10.1016/S0959-8049(97)10173-3 Mainwaring, 1997, Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy, Br J Cancer, 76, 1636, 10.1038/bjc.1997.609 Levine, 1999, Phase II trial of topotecan in advanced breast cancer: a Cancer and Leukemia Group B study, Am J Clin Oncol, 22, 218, 10.1097/00000421-199906000-00002 Fleming, 1998, Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer, J Clin Oncol, 16, 2032, 10.1200/JCO.1998.16.6.2032 Pantazis, 1993, Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts, Oncol Res, 5, 273 Verschraegen, 1998, A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel waterinsoluble topoisomerase I inhibitor, Anticancer Drugs, 9, 36, 10.1097/00001813-199801000-00004 Liehr, 1996, Pharmacokinetics of camptothecins administered orally, Ann N Y Acad Sci, 803, 157, 10.1111/j.1749-6632.1996.tb26384.x Heimann, 1998, Assessment of intratumoral vascularization (angiogenesis) in breast cancer prognosis, Breast Cancer Res Treat, 52, 147, 10.1023/A:1006123520603 Jacquemier, 1998, Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: a multiparametric and immunohistochemical analysis, J Pathol, 184, 130, 10.1002/(SICI)1096-9896(199802)184:2<130::AID-PATH19>3.0.CO;2-W Elledge, 1998, Prognostic and predictive value of p53 and p21 in breast cancer, Breast Cancer Res Treat, 52, 79, 10.1023/A:1006163101948 Bergh, 1995, Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy, Nat Med, 1, 1029, 10.1038/nm1095-1029 Slamon, 1989, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, 244, 707, 10.1126/science.2470152 McCann, 1991, Prognostic significance of cerbB- 2 and estrogen receptor status in human breast cancer, Cancer Res, 51, 3296 Aas, 1996, Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients, Nat Med, 2, 811, 10.1038/nm0796-811 Seth, 1997, A recombinant adenovirus expressing wild type p53 induces apoptosis in drug-resistant human breast cancer cells: a gene therapy approach for drug-resistant cancers, Cancer Gene Ther, 4, 383 Blagosklonny, 1998, Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cells, Int J Cancer, 75, 933, 10.1002/(SICI)1097-0215(19980316)75:6<933::AID-IJC17>3.0.CO;2-3 Liu, 1995, Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck, Cancer Res, 55, 3117 Shaw, 1992, Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line, Proc Natl Acad Sci U S A, 89, 4495, 10.1073/pnas.89.10.4495 Pirollo K, Liang X, Wen-Hua T, et al. Ligand-targeted, liposome-mediated p53 gene therapy in combination with radiation or chemotherapy leads to prostate tumor regression. Proceedings of the AACR-NCI-EORT International Conference, 1999 (Abstract #508). Liang X, Wen-Hau T, Pirollo K, et al. Chemosensitization of tumor cells by systematically delivered, ligand-directed, cationic liposome mediated wtp53 gene therapy. Proceedings of the AACR-NCI-EORT International Conference, 1999 (Abstract #535). Muller, 1998, p53 activates the CD95 (APO- 1/Fas) gene in response to DNA damage by anticancer drugs, J Exp Med, 188, 2033, 10.1084/jem.188.11.2033 Di Fiore, 1990, EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling, Science, 248, 79, 10.1126/science.2181668 Carter, 1992, Humanization of an antip185HER2 antibody for human cancer therapy, Proc Natl Acad Sci U S A, 89, 4285, 10.1073/pnas.89.10.4285 Sliwkowski, 1999, Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin), Semin Oncol, 26, 60 Baselga, 1996, Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer, J Clin Oncol, 14, 737, 10.1200/JCO.1996.14.3.737 Cobleigh, 1999, Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease, J Clin Oncol, 17, 2639, 10.1200/JCO.1999.17.9.2639 Slamon, 1998, Addition of Herceptin™ (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increased anticancer activity: a randomized, multinational controlled phase III trial, Proc Am Soc Clin Oncol, 17, 98a Norton, 1999, Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC), Proc Am Soc Clin Oncol, 18, 127a Fornier, 1999, Weekly (W) Herceptin (H) + 1 hour Taxol (T): phase II study in HER2 overexpressing (H2+) and nonoverexpressing (H2-) metastatic breast cancer (MBC), Proc Am Soc Clin Oncol, 18, 127a Arteaga, 1994, p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair, Cancer Res, 54, 3758 Pegram, 1998, Phase II study of receptorenhanced chemosensitivity using recombinant humanized antip185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment, J Clin Oncol, 16, 2659, 10.1200/JCO.1998.16.8.2659 Yu, 1991, Adenovirus type 5 E1A gene products act as transformation suppressors of the neu oncogene, Mol Cell Biol, 11, 1745, 10.1128/MCB.11.3.1745 Zhang, 1995, HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model, Oncogene, 10, 1947 Ueno, 1999, Issues in the development of gene therapy: preclinical experiments in E1A gene delivery, Oncol Rep, 6, 257 Xing, 1998, Safety study and characterization of E1A-liposome complex gene-delivery protocol in an ovarian cancer model, Gene Ther, 5, 1538, 10.1038/sj.gt.3300771 Hortobagyi, 1998, A phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer, Hum Gene Ther, 9, 1775, 10.1089/hum.1998.9.12-1775 Burstein, 2000, Herceptin and vinorelbine for HER2-positive metastatic breast cancer: a phase II study, Proc Am Soc Clin Oncol, 19, 102a